Generic medicines sustain health care systems A European analysis

Chimica Oggi

Volumn 29, Issue 2, 2011, Pages 28-33

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959232610     PISSN: 0392839X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. th of September 2006. European Commission (2007).
2. European Generic Medicines Association Health Economics Committee, How fo increase patient access to generic medicines in European healthcare systems. European Generic Medicines Association (2009).
3. Charles River Associates, Innovation In the pharmaceutical sector. European Commission (2004).
4. European Commission, Pharmaceutical Sector Inquiry Final Report. European Commission (2009).
5. B. Godman, B. Wettermark et al., Basic & Clin Pharm & Toxicology, 105(Suppl 1). p. 35 (2009.)
6. B. Godman, W. Shrank et al. Expert Rev Pharmacoecon Outcomes Res, 10(6), pp. 707-722 (2010).
7. European Generic Medicines Association, 2007 market review. European Generic Medicines Association (2007).
8. European Commission, Communication on the future of fhe pharmaceutical sector (COM/2008/0666). European Commission (2008).
9. Directive 1989/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of notional health insurance systems. Official Journal of the European Union L40 of 11 February 1989, pp. 8-11.
10. G10 High Level Group on Medicines, High Level Group on innovation and provision of medicines in the European Union: recommendations for action. European Commission (2002).
11. IHS Global Insight, National Audit Office finds further room for generic-associated savings in Norway. IHS Global Insight (2009).
12. Norwegian Medicines Agency, H. Festöy, K. Sveen et al. Pharmaceutical Pricing and Reimbursement Information: Norway. Gesundheit Österreich (2008).
13. Office of Fair Trading. The Pharmaceutical Price Regulation Scheme. Office of Fair Trading (2007).
14. C. Sermet, V. Andrieu et al., Appl Health Econ Health Policy, 8 (1), pp. 7-24 (2010).
15. S. Simoens, S. De Coster, Sustaining generic medicines markets in Europe. European Generic Medicines Association (2006).
16. Danish Medicine Agency, The use of "not S" In 2005. Danish Medicines Agency (2006).
17. INFARMED, Estudo de Opinião sobre Medicamentos Genéricos (Study of the opinion about generic medicines). INFARMED (2006).